SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kwality Pharma - Quaterly Results

30 Oct 2024 Evaluate
A decent increase of about 29.27% in the sales to Rs. 900.34 millions was observed for the quarter ended September 2024. The sales figure stood at Rs. 696.50 millions during the year-ago period.An average growth of 35.57% was recorded for the quarter ended September 2024 to Rs. 84.84  millions from Rs. 62.58 millions.OP of the company witnessed a marginal growth to 199.03 millions from 154.99 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 900.34 696.50 29.27 1701.13 1371.00 24.08 3071.72 2509.95 22.38
Other Income 2.22 2.34 -5.13 5.00 6.30 -20.63 18.30 29.41 -37.78
PBIDT 199.03 154.99 28.41 375.38 297.02 26.38 684.63 632.29 8.28
Interest 27.07 24.11 12.28 51.85 45.96 12.82 103.87 60.20 72.54
PBDT 171.96 130.88 31.39 323.53 251.06 28.87 509.77 406.80 25.31
Depreciation 46.13 48.77 -5.41 86.32 96.56 -10.60 195.11 149.19 30.78
PBT 125.83 82.11 53.25 237.21 154.50 53.53 314.66 257.61 22.15
TAX 40.99 19.53 109.88 68.70 37.46 83.40 74.83 62.93 18.91
Deferred Tax 0.26 -1.96 -113.27 -0.06 -2.25 -97.33 -4.37 1.37 -418.98
PAT 84.84 62.58 35.57 168.51 117.04 43.98 239.83 194.68 23.19
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 22.11 22.25 -0.66 22.07 21.66 1.86 22.29 25.19 -11.52

Kwality Pharma Share Price

1664.30 -82.70 (-4.73%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×